U.S. FDA panel recommends booster doses of Johnson & Johnsons COVID-19 vaccine

A U.S. Food and Drug Administration (FDA) advisory committee on Friday voted to recommend authorizing a second dose of Johnson & Johnson's COVID-19 vaccine.

The agency's Vaccines and Related Biological Products Advisory Committee voted unanimously, 19-0, to recommend authorization of a second dose as early as two months after the primary shot for anyone aged 18 and older.

The same committee on Thursday recommended Moderna booster shots to people aged 65 and older and other high-risk adults, in line with guidelines for Pfizer's vaccine.

The FDA usually follows the advice of the committee, and a final decision by its regulators could come within days.

Related Stories

• FDA panel recommends Moderna booster for people 65 and older and adults at high risk of exposure or severe illness
• Thailand needs 3-pronged collaboration to overcome crisis, Telenor researcher advises
• Thailand needs 3-pronged collaboration to overcome crisis, Telenor researcher advises